Officials of ultrasound vendor Advanced Technology Laboratoriescredit product cost reductions and the end of restructuring costsrelated to its acquisition of Interspec for a profitable firstquarter (end-March). Net income for the quarter rose to $3
Officials of ultrasound vendor Advanced Technology Laboratoriescredit product cost reductions and the end of restructuring costsrelated to its acquisition of Interspec for a profitable firstquarter (end-March).
Net income for the quarter rose to $3 million compared witha $274,000 loss in the same period of 1995. Sales of $94.8 millionwere up slightly compared with $94.4 million in last year's firstquarter, but the company reduced product sales costs and no longerfaced the restructuring charges that took the blame for most ofits first-quarter 1995 losses.
Chairman and chief executive Dennis Fill expects further improvementin the company's results due to its new sales effort in Japanand from a recent Food and Drug Administration ruling that willallow ATL to market the use of its Ultramark 9 HDI scanner forspecialized breast imaging applications.
Hitachi, ATL's distribution partner in Japan, is moving forwardwith its marketing campaign after gaining all necessary Japanesegovernment approvals in that country for the HDI 3000 premiumscanner, according to Fill. On April 12, ATL announced that theFDA had approved its premarket approval application to use Ultramark9 HDI as an adjunct to mammography to differentiate suspiciousmasses (SCAN 4/24/96).
Officials at the Bothell, WA, company also expect to beginshipments this month of HDI 3000 scanners equipped with the vendor'snew 3-D vascular visualization features.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.